Tuesday, July 7
Boursel
Sign in
Latest
Economy What Is a GLP-1 Drug, and Why Has It Reshaped Healthcare Investing?Companies Ocado Founder Tim Steiner Will Step Down as CEO in 2028Companies Novo Nordisk Puts Its Wegovy Weight-Loss Pill on UK Pharmacy ShelvesEconomy What Is a Golden Share?Companies Nintendo Will Stop Selling the Original Switch in Europe in 2027Markets Hughes Bondholders Weigh Their Options as a 1.5-Billion-Dollar August Deadline NearsTech Microsoft Cuts 4,800 Jobs and Overhauls Xbox, Even as AI Spending SoarsMarkets TeraWulf Surges After a 20-Year, $19 Billion Anthropic Data-Center LeaseEconomy What Is a GLP-1 Drug, and Why Has It Reshaped Healthcare Investing?Companies Ocado Founder Tim Steiner Will Step Down as CEO in 2028Companies Novo Nordisk Puts Its Wegovy Weight-Loss Pill on UK Pharmacy ShelvesEconomy What Is a Golden Share?Companies Nintendo Will Stop Selling the Original Switch in Europe in 2027Markets Hughes Bondholders Weigh Their Options as a 1.5-Billion-Dollar August Deadline NearsTech Microsoft Cuts 4,800 Jobs and Overhauls Xbox, Even as AI Spending SoarsMarkets TeraWulf Surges After a 20-Year, $19 Billion Anthropic Data-Center Lease

Topic: novo-nordisk

An Ozempic semaglutide injection pen
Economy
Monday, 7/6, 10:37 PM

What Is a GLP-1 Drug, and Why Has It Reshaped Healthcare Investing?

  • A single class of medicines, the GLP-1 drugs behind Ozempic, Wegovy, Mounjaro and Zepbound, has turned two drugmakers into among the most valuable companies on earth and rippled far beyond health care.
  • Here is what these drugs are, in plain English, and why investors cannot stop talking about them.

In brief

novo-nordisk — news and stories on this topic

This page collects all of Boursel's coverage of novo-nordisk. Follow the topic from one place: new stories appear here automatically as more is published. That way you stay on top of how the situation develops.

Looking for the bigger picture? Browse markets, the economy, companies and crypto, or head back to the front page for the day's top stories.